NasdaqGM:ZLABBiotechs
Zai Lab (ZLAB) Posts Positive Phase 3 Results In Autoimmune Myositis
Zai Lab (NasdaqGM: ZLAB) and argenx reported positive topline Phase 3 ALKIVIA trial results for VYVGART Hytrulo in autoimmune myositis.
The study is the first successful late stage trial in immune mediated necrotizing myopathy, a rare autoimmune muscle disease with no approved therapies.
Results showed statistically significant and clinically meaningful efficacy, with Zai Lab leading efforts in Greater China as part of a global trial.
This kind of progress in complex autoimmune conditions...